On the other hand, the treatment with the DNMT3A and FLT3-siRNA nanocarriers reduced the percentage of circulating hCD45-positive leukemia cells, which was compared on day 12 after treatment (Fig. 7C). The gene discussed is FLT3; the disease is leukemia.